[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pancreatitis-ap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pancreatitis-ap":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,74,105,127,153,176,206,231,249,273,302],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100053429","a-trial-of-the-arctx-cool-catheter-in-acute-pancreatitis-100053429",false,"NCT07698119","A Trial of the Arctx Cool Catheter in Acute Pancreatitis","Prospective, Multicenter, Randomized Controlled Trial of the Arctx Cool CatheterTM (ACC) Set in Patients With Acute Pancreatitis \"CHILL-AP\"","CHILL-AP","Inclusion Criteria:\n\n* Meets criteria for SIRS, defined as meeting two of the following four criteria:\n* Temperature \\>38°C (100.4°F) or \\\u003C36°C (96.8°F)\n* Heart rate \\>90 beats per minute\n* Respiratory rate \\>20 breaths per minute or PaCO2 \\\u003C32 mmHg\n* White blood cell (WBC) count \\>12,000\u002Fmm³ or \\\u003C4,000\u002Fmm³, or \\>10% immature (band) forms\n* Symptom onset within a window of time enabling ACC placement within a total of 48 hours\n* Diagnosis of acute pancreatitis by all three of the following criteria at the time of presentation (not referred), significant enough to require hospitalization:\n* Abdominal pain consistent with acute pancreatitis (acute onset of persistent, severe, epigastric pain, often radiating to the back)\n* Serum amylase and\u002For lipase greater than 3 times the upper limit of normal\n* Characteristic findings on contrast-enhanced CT (CECT). Note: If CT is not standard of care, it will be performed after the patient signs informed consent and all other eligibility criteria are met.\n* Signed written informed consent, and willingness and ability to complete follow-up requirements\n\nExclusion Criteria:\n\n* Serum creatinine \\>1.5 mg\u002FdL\n* Current treatment with pancreatic enzyme replacement therapy\n* Current treatment with hemodialysis or peritoneal dialysis\n* Active malignancy: a history of any invasive malignancy (except nonmelanoma skin cancer), unless treated with curative intent with no clinical signs or symptoms of the malignancy for at least five years\n* Pancreatic calcifications identified by the baseline contrast-enhanced CT (CECT)\n* History or evidence of pancreatic surgery\n* Uncorrected coagulation abnormalities or currently taking anti-coagulation medication\n* Known history of chronic pancreatitis\n* Prior history of acute pancreatitis requiring endoscopic drainage procedures and\u002For necrosectomy\n* Recurrent acute pancreatitis within 30 days\n* Known esophageal deformity or esophageal trauma, or known ingestion of acidic or caustic poisons\n* Recent trans-nasal surgery, severe maxillofacial trauma, or known diseases of the sinus tract\n* Nasopharyngeal or esophageal obstruction, diverticula, or stricture\n* Septal deviations\n* Known esophageal or gastric varices\n* History of esophageal, gastric, or duodenal surgery, specifically including gastric bypass\n* Reduced platelet count below 50,000\n* Less than 40 kg of body mass\n* Known allergy to any device component (polyurethane, barium sulphate, polyvinyl chloride, polycarbonate, nylon, ABS, polyethylene)\n* Female who is pregnant or nursing\n* Participated in another investigational drug or therapeutic medical device study within 30 days before randomization\n* Any history of congestive heart failure\n* History of peptic ulcer disease and\u002For H. pylori within the past year\n* Glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m² (GFR \\\u003C30)\n* Known or suspected diabetic nephropathy\n* Body mass index ≥40 kg\u002Fm², or BMI ≥35 kg\u002Fm² with significant comorbidity\n* Currently using GLP-1 receptor agonists (RAs)","ALL","22 Years","75 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Researchers will compare people who get the ACC Set plus standard of care to people who get standard of care alone. This will show whether adding the ACC Set helps.\n\nParticipants will:\n\nJoin one of two groups, chosen by chance: the ACC Set plus standard of care, or standard of care alone.\n\nHave the cooling tube in place for up to 3 days, if they are in the ACC Set group.\n\nHave blood tests and pain checks every few hours during their hospital stay. Return for follow-up visits about 7, 14, and 30 days later.",[28],"Acute Pancreatitis (AP)","NOT_YET_RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-08-01",{"date":37,"type":22},"2028-03-31",{"name":39,"class":40},"Arctx Medical, Inc.","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100641977","outpatient-versus-inpatient-management-of-mild-acute-pancreatitis-100641977","NCT07643961","Outpatient Versus Inpatient Management of Mild Acute Pancreatitis","Outpatient Versus Inpatient Management of Mild Acute Pancreatitis: A Randomised Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n* Age 18 years or older Diagnosis of acute pancreatitis based on at least two of three revised Atlanta (2012) criteria: characteristic abdominal pain; serum lipase or amylase ≥3× upper limit of normal; or characteristic imaging findings Classification as mild acute pancreatitis: SIRS score = 0 and HAPS score = 0 at emergency department presentation Ability to tolerate oral intake at the time of randomisation Provision of written informed consent Presence of a competent caregiver at home Residence within 30-45 minutes' travel time from the hospital Ability to communicate by telephone\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding Inability to maintain oral intake for reasons unrelated to acute pancreatitis Acute pancreatitis attributable to tumour, post-ERCP intervention, or abdominal trauma Concurrent choledocholithiasis with or without cholangitis Chronic pancreatitis or history of recurrent acute pancreatitis (≥2 prior episodes) ASA physical status classification ≥ 3 Clinical or radiological features suggesting moderately severe or severe acute pancreatitis Alcohol withdrawal syndrome No competent caregiver at home Residence more than 30-45 minutes from the hospital Inability to communicate by telephone or equivalent means","18 Years",{"count":50,"type":22},150,[25],"Acute pancreatitis is a sudden inflammation of the pancreas that causes severe abdominal pain. Most cases are mild and get better within a few days with basic supportive treatment such as fluids and pain relief. Currently, all patients with acute pancreatitis are admitted to hospital, even those with a very low risk of complications. This study will test whether patients with mild acute pancreatitis can be safely sent home with close follow-up (telephone calls on days 1, 2, and 3 after discharge and a clinic visit on day 4) instead of staying in hospital. Patients will be randomly assigned to either home management or standard hospitalization. We will compare the rate of treatment failure at 30 days between the two groups. We expect that home management will be as safe as hospitalization, while being more convenient for patients and less costly for the health system.",[28,54],"Biliary Pancreatitis",[56,57,58,59,60,61,62],"acute pancreatitis","outpatient","ambulatory","non-inferiority","randomised controlled trial","HAPS","SIRS","2026-06-10",{"date":65,"type":33},"2026-06-12",{"date":67,"type":22},"2026-07-01",{"date":69,"type":22},"2027-03-31",{"name":71,"class":72},"Center for Traumatology and Major Burns, Ben Arous","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":73},"100642685","predictive-performance-of-news-2-and-news-calcium-scores-for-in-hospital-mortality-in-older-patients-with-acute-pancreatitis-100642685","NCT07640971","Predictive Performance of NEWS-2 and NEWS-Calcium Scores for In-Hospital Mortality in Older Patients With Acute Pancreatitis","Comparison of the Predictive Performance of NEWS-2 and NEWS-Calcium Scores on In-Hospital Mortality in Patients Aged 65 Years and Older Diagnosed With Acute Pancreatitis in the Emergency Department.","NEWS","Inclusion Criteria:\n\n* Age 65 years or older.\n* Admission to the emergency department with a diagnosis of acute pancreatitis during the study period.\n* Diagnosis of acute pancreatitis established according to clinical presentation, serum pancreatic enzyme levels, and\u002For imaging findings.\n* Availability of admission vital parameters required to calculate the National Early Warning Score 2 (NEWS-2).\n* Availability of serum calcium measurement at emergency department admission.\n* Availability of in-hospital clinical outcome data.\n\nExclusion Criteria:\n\n* Age younger than 65 years.\n* Absence of a confirmed diagnosis of acute pancreatitis.\n* Missing data required to calculate NEWS-2 or NEWS-Calcium scores.\n* Missing serum calcium measurement at admission.\n* Incomplete medical records or unavailable in-hospital outcome data.\n* Transfer to another hospital before clinical outcome assessment.\n* Recurrent admissions during the study period; only the first eligible admission will be analyzed.","65 Years",{"count":84,"type":22},350,"1 Month","OBSERVATIONAL","Acute pancreatitis is an important gastrointestinal emergency that may lead to mortality, particularly in older patients. This retrospective, single-center observational prognostic validation study aims to compare the predictive performance of the National Early Warning Score 2 (NEWS-2) and NEWS-Calcium scores for in-hospital mortality in patients aged 65 years and older diagnosed with acute pancreatitis in the emergency department.\n\nElectronic medical records of eligible patients will be reviewed retrospectively. Demographic characteristics, vital signs, serum calcium levels, clinical outcomes, intensive care unit admission, organ failure, length of hospital stay, and in-hospital mortality will be recorded. NEWS-2 will be calculated using vital parameters at admission, while the NEWS-Calcium score will be obtained by adding a calcium-based score to NEWS-2.\n\nThe primary outcome will be in-hospital mortality. Secondary outcomes will include intensive care unit admission, severe acute pancreatitis, persistent organ failure, and length of hospital stay. The predictive performances of the scores will be compared using ROC curve analysis, AUC values, and the DeLong test. This study aims to identify the most appropriate early prognostic score for older patients with acute pancreatitis and to support clinical decision-making in emergency settings.",[28,89,90],"News-2","Prediction of In-Hospital Mortality in Older Patients With Acute Pancreatitis",[92,93,94,95],"Acute Pancreatitis","In-Hospital Mortality","Older Adults","Emergency Department Risk Stratification","2026-06-06",{"date":98,"type":33},"2026-06-11",{"date":100,"type":22},"2026-07-15",{"date":102,"type":22},"2026-10-15",{"name":104,"class":72},"Antalya Health Sciences University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":73},"100639854","phase-4-heparin-to-prevent-organ-failure-in-acute-pancreatitis-100639854","NCT07609771","Heparin to Prevent Organ Failure in Acute Pancreatitis","Unfractionated Heparin for Organ Failure Prevention in Acute Pancreatitis: A Randomized Trial","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Confirmed clinical diagnosis of acute pancreatitis based on meeting at least two of the following three revised Atlanta criteria: (1) acute onset of severe, persistent upper abdominal pain; (2) serum amylase or lipase levels elevated to at least three times the upper limit of normal; (3) characteristic findings of acute pancreatitis on cross-sectional abdominal imaging.\n* Presentation to the hospital and initiation of the trial protocol within 24 hours of the onset of symptoms.\n* Absence of systemic organ failure at the baseline assessment during initial hospital admission.\n\nExclusion Criteria:\n\n* Baseline organ failure already present at the time of initial hospital admission (defined as a Modified Marshall Score of 2 or more in any organ system).\n* Patients with a known history of chronic pancreatitis or recurrent episodes of pancreatitis.\n* History of hypersensitivity, allergy, or known adverse reactions to heparin, low molecular weight heparins, or related anticoagulants.\n* Active clinically significant bleeding, recent major hemorrhage, known bleeding diathesis, or severe thrombocytopenia (platelet count less than 100,000\u002FmcL).\n* Existing indication for therapeutic systemic anticoagulation (such as active deep vein thrombosis, pulmonary embolism, mechanical heart valves, or atrial fibrillation).\n* Pregnant or lactating females.\n* Refusal to provide informed consent to participate in the study.",{"count":113,"type":22},100,[115],"PHASE4","This clinical trial is designed to evaluate whether adding a standard blood-thinning medication, Unfractionated Heparin, to standard hospital care can help prevent severe organ failure in patients admitted with acute pancreatitis.\n\nAcute pancreatitis is a sudden and severe inflammation of the pancreas. During this condition, intense inflammation can trigger a hypercoagulable state (excessive blood clotting) in the small blood vessels supplying vital organs. This microvascular clotting can block normal blood flow, starving tissues of oxygen and potentially leading to dangerous, life-threatening multi-organ failure involving the lungs, kidneys, or heart. Currently, standard medical care for acute pancreatitis is purely supportive-consisting of intensive intravenous fluid hydration, pain management, and nutritional support-without any specific targeted drug therapy to halt the disease's progression.\n\nIn this study, participating patients are randomly assigned into one of two balanced groups using a randomized lottery method upon their admission to the surgical unit:\n\n1. The Control Group: Receives standard supportive hospital medical care only.\n2. The Intervention Group: Receives the same standard supportive medical care plus a continuous, carefully monitored intravenous infusion of Unfractionated Heparin.\n\nThe primary objective of the study is to determine if early initiation of this standard anticoagulant therapy preserves blood flow, dampens the severe inflammatory cascade, and successfully prevents the development of new or worsening organ failure. The study will also evaluate secondary clinical endpoints, including the total duration of the patient's hospital stay and the general safety profile of the intervention by monitoring for any adverse bleeding complications.",[28],"2026-05-20",{"date":120,"type":33},"2026-05-27",{"date":122,"type":22},"2026-06",{"date":124,"type":22},"2026-11",{"name":126,"class":72},"Allied Hospital Faisalabad",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":133,"enrollmentInfo":134,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":73},"100582731","bowel-sound-in-predicting-the-severity-of-acute-pancreatitis-protocol-of-a-prospective-multi-center-study-100582731","NCT06867120","Bowel Sound in Predicting the Severity of Acute Pancreatitis: Protocol of a Prospective, Multi-center Study","Inclusion criteria:\n\n1. Aged between 18 and 85 years old.\n2. Meet the diagnostic criteria for AP, at least two of the following three: (a) characteristic abdominal pain; (b) serum amylase and lipase levels are greater than three times the upper limit of normal; (c) abdominal images with typical manifestations of AP.\n3. AP patients within 48 hours of onset.\n4. The patient or family members understand the study protocol and sign the informed consent form.\n\nExclusion criteria:\n\nThe patients who fulfill any of the following criteria will be excluded:\n\n1. Patients with serious conditions requiring surgery and abdominal lavage.\n2. Pregnant women.\n3. The patients with muscle and nerve disorders, chronic pancreatitis, inflammatory bowel disease, cancer, and irritable bowel syndrome.\n4. The patients with severe digestive, respiratory, cardiovascular, hematological, endocrine, psychiatric, and infectious diseases.\n5. The patients have a history of abdominal surgery (except appendectomy or cholecystectomy).\n6. Allergic to silicone, polycarbonate materials or medical plaster. The intake of antibiotic, probiotics, and Chinese herbal medicine will be recorded before the collection of the swabs and will not be considered as exclusion criteria.","85 Years",{"count":135,"type":22},352,"Introduction: Acute pancreatitis (AP) is a common condition, with 20% of cases progressing to severe acute pancreatitis (SAP), which is associated with a poor prognosis. Early identification of patients likely to progress to SAP is crucial for timely intervention. This study aims to use bowel sound monitoring to predict early progression to SAP in AP patients.\n\nMethods and analysis: This study is a prospective, multi-center prognostic study . Investigators will consecutively recruit newly diagnosed acute pancreatitis (AP) patients at emergency departments across three centers from December 2023. Upon enrollment, each patient will undergo continuous bowel sound monitoring for at least 48 hours using standardized equipment and procedures. The primary outcome is the occurrence of SAP during hospitalization. Collected bowel sound data will be analyzed by an unsupervised automated algorithm to estimate a bowel sound activity index, which serves as the main diagnostic indicator for SAP. This process will be fully blinded to patients' SAP status. Investigators will calculate the ROC curve and area under the curve (AUC) for the bowel sound activity index's ability to diagnose SAP. Additionally, this study will perform exploratory analyses on differences in gut microbiota and serum intestinal permeability markers (diamine oxidase, D-lactic acid, and bacterial endotoxin) between patients with and without SAP. Investigators will also assess whether bowel sound monitoring can reflect these inter-group differences.\n\nStrengths and limitations of the study:\n\n1. Our research aims to monitor bowel sounds in real-time and dynamically, providing an objective tool for monitoring intestinal activity in AP patients.\n2. Our research might offer an objective tool to evaluate bowel sounds, aiding in assessing AP patients' intestinal function and complementing existing score systems like the modified Marshall score.\n3. By detecting bowel sounds in the early stage of AP, investigators could better monitor intestinal function, which might aid in predicting the prognosis of AP patients.\n4. Our monitoring system's main limitation is its difficulty in pinpointing bowel sound changes in specific intestinal segments due to its detection across the entire abdomen.",[28,138],"Severe Acute Pancreatitis",[140,56,141,142],"bowel sound","intestinal function","prediction","RECRUITING","2026-04-02",{"date":146,"type":33},"2026-04-06",{"date":148,"type":33},"2024-04-01",{"date":150,"type":22},"2027-12-31",{"name":152,"class":72},"Peking Union Medical College Hospital",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":73},"100627612","retrospective-analysis-of-acute-pancreatitis-after-percutaneous-mechanical-thrombectomy-in-treatment-of-thrombotic-disorders-100627612","NCT07450898","Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders","Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders (The RATIO Study)","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Patients with thrombotic peripheral vascular diseases treated by percutaneous mechanical thrombectomy;\n* Patients developed acute pancreatitis within 14 days after percutaneous mechanical thrombectomy;\n* Patients with written informed consent.\n\nExclusion Criteria:\n\n* Patients with acute pancreatitis attributed to other confirmed causes;\n* Patients unable or unwilling to participate in the study.",{"count":161,"type":22},10,"Acute pancreatitis is a rare complication after percutaneous mechanical thrombectomy in treatment of thrombotic disorders. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient\u002Fprocedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.",[28,164],"Thrombotic Disorders",[166],"Thrombectomy","2026-03-03",{"date":169,"type":33},"2026-03-05",{"date":171,"type":33},"2016-01-01",{"date":173,"type":22},"2026-12-31",{"name":175,"class":72},"RenJi Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":183,"enrollmentInfo":184,"targetDuration":186,"studyType":86,"phases":4,"briefSummary":187,"conditions":188,"keywords":195,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":73},"100626755","ai-powered-precision-decision-making-for-pancreatic-diseases-100626755","NCT07439757","AI-Powered Precision Decision-Making for Pancreatic Diseases","A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT","Inclusion Criteria:\n\n* Clinically suspected pancreatic disease.\n* Scheduled to undergo contrast-enhanced CT.\n* Signed informed consent form indicating agreement to participate.\n\nExclusion Criteria:\n\n* History of pancreatic surgery.\n* Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal\u002Fhepatic dysfunction.\n* Suboptimal image quality affecting diagnosis.\n* Concurrent participation in another interventional clinical trial.\n* Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.","80 Years",{"count":185,"type":22},2000,"1 Year","This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery\u002Ftreatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.",[189,190,191,192,193,194,28],"Pancreatic Cancer","Diagnose Disease","IPMN, Pancreatic","Pancreatic Cystic Lesions","Chronic Pancreatitis","Pancreatic Neuroendocrine Tumor",[196],"Artificial Intelligence (AI), Deep Learning, Contrast-Enhanced CT, Multicenter Clinical Trial, Real-World Study","2026-02-23",{"date":199,"type":33},"2026-02-27",{"date":201,"type":22},"2026-03-01",{"date":203,"type":22},"2029-10-31",{"name":205,"class":72},"Changhai Hospital",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":19,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":73},"100623372","nasojejunal-feeding-versus-oral-feeding-following-endoscopic-drainage-of-walled-off-pancreatic-necrosis-100623372","NCT07395778","Nasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis","Nasojejunal Feeding Versus Oral Feeding Following Endoscopic Drainage of Walled Off Pancreatic Necrosis: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n1. Patients of acute pancreatitis (AP) with 18-75 years of age\n2. Patients with symptomatic WON requiring EUS guided transluminal drainage\n3. Provision of written informed consent\n\nExclusion Criteria:\n\n1. Patients with collection not amenable for EUS guided drainage (distance of WON \\>1 cm from the gastrointestinal lumen)\n2. Known malignancy or immunocompromised state\n3. Previous upper gastrointestinal(GI) surgery interfering with absorption\n4. Active GI bleeding\n5. GI obstruction, ileus or persistent vomiting\n6. Patients moribund to undergo endoscopic procedure (Glasgow coma scale \\\u003C8 or patients on ventilatory support)\n7. Patients with irreversible coagulopathy like platelets \\\u003C50,000\u002Fmm3 and\u002For INR\\>1.5\n8. Pregnant or lactating female",{"count":214,"type":22},50,[25],"The goal of this randomized control trial is to assess whether nasojejunal feed is better than oral nutrition in patients who are undergoing endoscopic cystogastrostomy of walled off necrosis following acute pancreatitis. It will also try to answer, the incidence of infections and feed tolerance.\n\nThe main question it tries to answer is\n\n1. whether nasojejunl feed is better than oral feed in patients undergoing endoscopic cystogastrostomy in walled off necrosis following acute pancreatitis\n2. How much infections they develop, whether they are able to tolerate the feed, weight gain and reintervention rates in each group",[218,28,219],"Walled Off Pancreatic Necrosis","Endoscopic Ultrasound-Guided Drainage",[221],"Cystogastrostomy, Walled off pancreatic necrosis, nutrition","2026-01-31",{"date":224,"type":33},"2026-02-09",{"date":226,"type":33},"2025-10-18",{"date":228,"type":22},"2027-01",{"name":230,"class":72},"Post Graduate Institute of Medical Education and Research, Chandigarh",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":235,"conditions":238,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":4},"100610897","utilization-of-cbc-derived-inflammatory-indices-in-assessing-severity-and-prognosis-of-acute-pancreatitis-100610897","NCT07233551","Utilization of CBC-Derived Inflammatory Indices in Assessing Severity and Prognosis of Acute Pancreatitis.","Inclusion Criteria:\n\n1. adult patients aged 18 years old or older.\n2. patients with acute pancreatitis who were treated in our hospital from January 2019 to March 2025.\n\nExclusion Criteria:\n\n1. history of chronic kidney disease\n2. Pregnancy.\n3. History of neoplasm\n4. present of acute infection\n5. history of hematological diseases",{"count":113,"type":22},[28,239],"Inflammatory Indices","2025-11-17",{"date":242,"type":33},"2025-11-18",{"date":244,"type":22},"2025-12-01",{"date":246,"type":22},"2026-12-30",{"name":248,"class":72},"Assiut University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":260,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100600169","endoscopic-pancreatic-duct-stent-placement-versus-conventional-approach-in-the-treatment-of-early-phase-acute-pancreatitis-100600169","NCT07093996","Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis","Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis: International Multicenter Controlled Randomized Prospective Study Protocol","Inclusion Criteria:\n\n1. Diagnosis of acute pancreatitis confirmed on the basis of at least 2 of the 3 diagnostic criteria according to the revised Atlanta classification\n2. Presence of organ failure signs (moderate and severe pancreatitis)\n3. Informed consent of the patient\n\nExclusion Criteria:\n\n1. Presence of other indications for endoscopic intervention on the major duodenal papilla (biliary pancreatitis with cholangitis, calculus of the major duodenal papilla, stenosis of the major duodenal papilla, etc.)\n2. Previous surgical interventions on the major duodenal papilla\n3. Diverticula of the major duodenal papilla\n4. Pregnancy\n5. Shock\n6. Coagulopathy (INR\\>1.5, blood platelets \\\u003C 50\\*109\u002Fl",{"count":21,"type":22},[25],"The planned multicenter randomized study is aimed to assess the efficacy and safety of endoscopic pancreatic duct stenting in adult patients with acute pancreatitis. It is planned to include patients with early-stage nonbiliary pancreatitis in the study.",[28],[56,261,262],"endoscopic pancreatic duct stent placement","pancreatic necrosis","2025-07-28",{"date":265,"type":33},"2025-07-30",{"date":267,"type":22},"2025-09-01",{"date":269,"type":22},"2027-02-01",{"name":271,"class":72},"Almazov National Medical Research Centre",7,{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":73},"100580263","dextran-40-plus-ringers-lactate-vs-ringers-lactate-alone-for-fluid-resuscitation-in-acute-pancreatitis-100580263","NCT06835023","Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis","A Randomized Controlled Trial Evaluating Fluid Resuscitation in Acute Pancreatitis: Dextran 40 and Ringer's Lactate (1:3 Ratio) Versus Ringer's Lactate Alone","Inclusion Criteria:\n\n* adults (≥18 years) diagnosed with mild or moderate acute pancreatitis\n* must provide written informed consent for study participation.\n\nExclusion Criteria:\n\n* patients who decline to provide informed consent.\n* patients are non-compliant with treatment and follow-up visits.\n* pregnant individuals.\n* patients requiring concomitant treatment that is contraindicated within the study protocol.\n* patients who develop conditions that contraindicate the administration of the investigational medication.\n* patients experiencing severe adverse reactions necessitating treatment discontinuation.",{"count":113,"type":22},[25],"This clinical trial aims to learn if a combination of Dextran 40 and Ringer's lactate solution can improve fluid resuscitation in mild and moderate acute pancreatitis (AP) and prevent complications. The main questions it aims to answer are:\n\nDoes early fluid resuscitation with Dextran 40 plus Ringer's lactate improve patient outcomes compared to Ringer's alone? Does this treatment reduce inflammation, organ failure, and the need for intensive care unit (ICU) admission? Researchers will compare Dextran 40 plus Ringer's lactate to Ringer's alone to see if the combination therapy is more effective in reducing disease severity and complications.\n\nParticipants will:\n\nReceive either Dextran 40 plus Ringer's lactate (1:3 ratio) or Ringer's lactate alone.\n\nHave blood tests every 24 hours to measure inflammation and organ function. Be monitored for changes in disease severity, need for ICU admission, and hospitalization duration.\n\nThis study will help determine the best fluid resuscitation strategy for treating mild and moderate acute pancreatitis.",[28,284,285],"Acute Pancreatic Fluid Collection","Fluid Resuscitation",[287,288,289,290,291],"Fluid resuscitation","Acute pancreatitis","Dextran","Ringer Lactat solution","combination colloid-crystalloid","2025-02-18",{"date":294,"type":33},"2025-02-20",{"date":296,"type":33},"2022-01-10",{"date":298,"type":22},"2025-05-12",{"name":300,"class":301},"Satu Mare County Emergency Hospital","OTHER_GOV",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":73},"100579797","neutrophil-creatinine-index-in-patients-with-acute-pancreatitis-assessment-of-severity-and-outcome-100579797","NCT06828965","Neutrophil-Creatinine Index in Patients with Acute Pancreatitis: Assessment of Severity and Outcome","Inclusion Criteria:\n\n* All patients with AP will be enrolled.\n* Both sexes\n* Age of patient \\> 18 years old\n\nExclusion Criteria:\n\n* Age less than 18 years old\n* Pancreatic cancer\n* Picture of chronic pancreatitis\n* Recurrent pancreatitis\n* pregnancy, end-stage renal disease, hematological disorders, pancreatic carcinoma or cholangiocarcinoma, and incomplete records.","60 Years",{"count":113,"type":22},"Acute pancreatitis is a disease that usually has a mild disease course. However, around 20-30% of the patients develop severe complications. Persistent organ failure, with or without the presence of local complications such as (peri-) pancreatic necrosis and secondary infections, is the main determinant for mortality, and these patients are classified as having severe acute pancreatitis according to the revised Atlanta classification . The most widely used classification systems for determining the severity and course of AP are the revised Atlanta classification and the Bedside Index of Severity in Acute Pancreatitis (BISAP). According to the revised Atlanta classification, the severity of AP is graded as mild acute pancreatitis (MAP), moderately severe acute pancreatitis (MSAP), or severe acute pancreatitis (SAP) . In addition to the revised Atlanta classification and BISAP, several other prognostic scoring systems and classifications have been developed to predict the severity of AP. Ranson's criteria, the Acute Physiology and Chronic Health Evaluation (APACHE) II score, the Modified Glasgow Prognostic Score, and the Balthazar index are other commonly used prognostic systems . Most of these scoring systems include multiple determinants or parameters that must be noted 24 to 48 h after hospitalization, and the estimation of the severity of AP is delayed until 48 h after hospitalization. Thus, these scoring systems are of limited use at admission. On the other hand, in view of the complexity of prognostic scoring systems, several studies have been conducted on the role of simple laboratory parameters and indices in predicting the disease severity of AP and mortality . The most widely studied laboratory parameters and indices are the white blood cell count (WBC), neutrophil count, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), C-reactive protein (CRP), and procalcitonin. These laboratory parameters have also been used as part of several prognostic scoring systems. Nevertheless, none of the laboratory parameters or prognostic scoring systems can predict the severity of AP or MOF with sufficient accuracy . Moreover, it is not easy to predict the course and severity of acute pancreatitis at the first assessment of hospital admission. At the time of admission, most laboratory parameters are insufficient to differentiate mild disease from severe disease, and changes in laboratory parameters over time, including inflammatory markers and parameters related to organ\u002Fsystem dysfunction, provide important clues regarding the course of the disease . On the other hand, there is a need for simple, reliable, widely used parameters at admission for predicting the course of the disease. Sahin (2024) found a new index named the neutrophil-creatinine index (NCI), which was established based on the levels of neutrophil count and creatinine, to predict the severity of AP at admission . It's known that neutrophil infiltration and activation is one of the early events in acute pancreatitis and results in higher neutrophil count values at admission. Similarly, higher creatinine values at admission indicate renal hypoperfusion, which is associated with third-space leakage resulting from a systemic inflammatory state. It was assumed that the NCI may serve as an efficient test to represent the combination of inflammatory response and organ dysfunction .",[28],[313],"acute pancreatitis, severity, accuracy, mortality","2025-02-13",{"date":316,"type":33},"2025-02-17",{"date":318,"type":22},"2025-03-27",{"date":173,"type":22},{"name":248,"class":72}]